Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus (HBV) infection, met its primary efficacy endpoint. The data show that Viread is non-inferior to the company's once-daily antiviral drug Hepsera(R) (adefovir dipivoxil) among patients with "e" antigen (HBeAg)-positive chronic hepatitis B. The primary efficacy endpoint, the proportion of patients with a complete response at week 48, was defined by serum HBV DNA levels below 400 copies/mL and histologic improvement characterized by at least a two point reduction in the Knodell necroinflammatory score (a measure of necro-inflammation - an inflammatory process in the liver including or leading to death of liver cells) with no concurrent worsening of fibrosis (scarring of liver tissue).

At 48 weeks, 66.5 percent of patients in the Viread arm (n=176) had a complete response compared to 12.2 percent in the Hepsera arm (n=90; p less than 0.001). The most commonly observed treatment-emergent adverse events of moderate intensity or higher were abdominal pain, back pain, headache, respiratory infections and transaminase elevations. The incidence of these events was comparable between the Viread and Hepsera arms of the study. In addition, the most frequently observed grade 3 or 4 laboratory abnormalities were elevations in transaminase and serum amylase and were comparable between the two arms. Full study results will be submitted for presentation at an upcoming scientific meeting.

Study 103 is the second of two Phase III pivotal studies evaluating the efficacy, safety and tolerability of Viread for the treatment of chronic hepatitis B to have met its primary efficacy endpoint. Earlier this month, the co
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... , , MONMOUTH JUNCTION, ... from a Phase II clinical trial in non-cystic fibrosis (CF) ... (liposomal amikacin for inhalation). The Phase II data indicated that ... clinical benefit compared to placebo as measured by patient and ...
... , TARRYTOWN, N.Y., Sept. 14 ... announced the completion of patient enrollment in two randomized, double-masked, ... of the neovascular form of age-related macular degeneration (wet AMD). ... of Efficacy and Safety in Wet AMD) program, VEGF Trap-Eye ...
Cached Medicine Technology:Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 2Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 3Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 2Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 3Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 5
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/26/2014)... Parker & Sons, Inc. a ... heating, cooling and plumbing contractor services throughout Arizona ... in 2014 with regard to air-conditioning systems. Residential ... known for its incredibly hot summers. Working with ... and details of a wide variety of systems ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3
... Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and ... PDLI ) and Alexion Pharmaceuticals, Inc. (Nasdaq: ... have entered into a definitive license agreement and settlement agreement ... humanized antibody, Soliris(R) (eculizumab) and PDL,s patents known as the ...
... Jan. 5 The Ensign Group, Inc. (Nasdaq: ... has acquired Southland Healthcare Center, a 150-bed skilled ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"This is a strategic acquisition, and ...
... The Ensign Group, Inc. (Nasdaq: ... Cabrillo Care Center, a 156-bed skilled nursing facility ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"We are excited to extend our ...
... Campaign of Upscale Properties in Denver, Colorado , ... ... estate auction marketing firm, LFC Group of Companies, launched a new ... residential real estate website, Freedom Realty Exchange ( FRE.com/284R3 ). The ...
... Help us, help the Red Cross meet the winter demand for blood. January ... Wilmington MA. We,ll give you FREE oil change if you,re one of the first ... ... the American Red Cross are asking people to come out and give blood as ...
... informatics platform, OnCore®, achieved another milestone this ... multidisciplinary research organization. At the end of ... Clinical and Translational Research (UWICTR) began using ... collection and administration needs. OnCore is the ...
Cached Medicine News:Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3Health News:The Ensign Group Acquires Texas Skilled Nursing Facility 2Health News:The Ensign Group Acquires California Skilled Nursing Facility 2Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 2Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 3Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 4Health News:Boston Hyundai Dealer Teams up With the Red Cross to Save Lives 2Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 2Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 3Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 4
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... Increase Staff Protection With Medline's Sterile Suction Catheters ... 16 Fr and 18 Fr), ,Medline is ... U.S. We manufacture most of our suction products ... our customers' expectations. We manufacture, supply and directly ...
... Catheters are available in ... atraumatic DeLee tip with staggered ... tip. Two types of catheter ... deliver easy fingertip control with ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
Medicine Products: